Schedule of Assumptions to Estimate the Stock-based Compensation Expense (Details) - Titan Pharmaceuticals Inc [Member] - USD ($)		2 Months Ended		12 Months Ended
		Sep. 30, 2022	[1]	Dec. 31, 2024		Dec. 31, 2023
Weighted-average risk-free interest rate						4.10%
Expected dividend payments
Expected holding period (years)		12 months		0 years	[2]	5 years 3 months 10 days	[2]
Weighted-average volatility factor	[3]					1.10%
Estimated forfeiture rates for options granted	[4]					7.00%

[1] Other tax payable mainly include the sales and service tax (“SST”) payable.

[2] Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior.

[3] Weighted average volatility is based on the historical volatility of our common stock.

[4] Estimated forfeiture rates are based on historical data.